Mouaz Alsawas

Mouaz Alsawas

Auto-generated profile, based on publicly available information

Mouaz Alsawas

Mayo Clinic Evidence-based Practice Center, Mayo Clinic, Rochester, Minnesota, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2018 in American Journal of Medical Quality
Verified
Journal Article
Closed access
LDLubna Daraz
Lubna Daraz
AMAllison S. Morrow
Allison S. Morrow
OPOscar J. Ponce
Oscar J. Ponce
WFWigdan Farah
Wigdan Farah
AKAbdulrahman Katabi
Abdulrahman Katabi
MMM. Hassan Murad
M. Hassan Murad
Online health information should meet the reading level for the general public (set at sixth-grade level). Readability is a key requirement for information to be helpful and improve quality of care. The authors conducted a systematic review to evaluate the readability of online health information in the United States and Canada. Out of 3743 references, the authors included 157 cross-sectional studies evaluating 7891 websites using 13 readability scales. The mean readability grade level across websites ranged from grade 10 to 15 based on the different scales. Stratification by specialty, health condition, and type of organization producing information revealed the same findings. In conclusion, online health information in the United States and Canada has a readability level that is inappropriate for general public use. Poor readability can lead to misinformation and may have a detrimental effect on health. Efforts are needed to improve readability and the content of online health information.

15 March 2024 in Hepatology
Verified
Journal Article
Closed access
RSRichard K. Sterling
Richard K. Sterling
ADAndres Duarte-Rojo
Andres Duarte-Rojo
KPKeyur Patel
Keyur Patel
SASumeet K. Asrani
Sumeet K. Asrani
MAMouaz Alsawas
Mouaz Alsawas
DRDon C. Rockey
Don C. Rockey
An abstract is unavailable. This article is available as a PDF only.

15 March 2024 in Hepatology
Verified
Journal Article
Closed access
RSRichard K. Sterling
Richard K. Sterling
KPKeyur Patel
Keyur Patel
ADAndres Duarte-Rojo
Andres Duarte-Rojo
SASumeet K. Asrani
Sumeet K. Asrani
MAMouaz Alsawas
Mouaz Alsawas
DRDon C. Rockey
Don C. Rockey
An abstract is unavailable. This article is available as a PDF only.

15 March 2024 in Hepatology
Verified
Journal Article
Closed access
ADAndres Duarte-Rojo
Andres Duarte-Rojo
BTBachir Taouli
Bachir Taouli
DLDaniel H. Leung
Daniel H. Leung
DLDeborah Levine
Deborah Levine
TNTarek Nayfeh
Tarek Nayfeh
RSRichard K. Sterling
Richard K. Sterling
Background and Aims: Transient elastography (TE), shear wave elastography, and/or magnetic resonance elastography (MRE), each providing liver stiffness measurement (LSM), are the most studied imaging-based noninvasive liver disease assessment (NILDA) techniques. To support the American Association for the Study of Liver Diseases guidelines on NILDA, we summarized the evidence on the accuracy of these LSM methods to stage liver fibrosis (F). Approach and Results: A comprehensive search for studies assessing LSM by TE, shear wave elastography, or MRE for the identification of significant fibrosis (F2-4), advanced fibrosis (F3-4), or cirrhosis (F4), using histopathology as the standard of reference by liver disease etiology in adults or children from inception to April 2022 was performed. We excluded studies with <50 patients with a single disease entity and mixed liver disease etiologies (with the exception of HCV/HIV coinfection). Out of 9447 studies, 240 with 61,193 patients were included in this systematic review. In adults, sensitivities for the identification of F2-4 ranged from 51% to 95%, for F3-4 from 70% to 100%, and for F4 from 60% to 100% across all techniques/diseases, whereas specificities ranged from 36% to 100%, 74% to 100%, and 67% to 99%, respectively. The largest body of evidence available was for TE; MRE appeared to be the most accurate method. Imaging-based NILDA outperformed blood-based NILDA in most comparisons, particularly for the identification of F3-4/F4. In the pediatric population, imaging-based NILDA is likely as accurate as in adults. Conclusions: LSM from TE, shear wave elastography, and MRE shows acceptable to outstanding accuracy for the detection of liver fibrosis across various liver disease etiologies. Accuracy increased from F2-4 to F3-4 and was the highest for F4. Further research is needed to better standardize the use of imaging-based NILDA, particularly in pediatric liver diseases.

15 March 2024 in Hepatology
Verified
Journal Article
Closed access
KPKeyur Patel
Keyur Patel
SASumeet K. Asrani
Sumeet K. Asrani
MFMaria Isabel Fiel
Maria Isabel Fiel
DLDeborah Levine
Deborah Levine
DLDaniel H. Leung
Daniel H. Leung
RSRichard K. Sterling
Richard K. Sterling
Background and Aims: Blood-based biomarkers have been proposed as an alternative to liver biopsy for noninvasive liver disease assessment in chronic liver disease. Our aims for this systematic review were to evaluate the diagnostic utility of selected blood-based tests either alone, or in combination, for identifying significant fibrosis (F2-4), advanced fibrosis (F3-4), and cirrhosis (F4), as compared to biopsy in chronic liver disease. Approach and Results: We included a comprehensive search of databases including Ovid MEDLINE(R), EMBASE, Cochrane Database, and Scopus through to April 2022. Two independent reviewers selected 286 studies with 103,162 patients. The most frequently identified studies included the simple aspartate aminotransferase-to-platelet ratio index and fibrosis (FIB)-4 markers (with low-to-moderate risk of bias) in HBV and HCV, HIV-HCV/HBV coinfection, and NAFLD. Positive (LR+) and negative (LR−) likelihood ratios across direct and indirect biomarker tests for HCV and HBV for F2-4, F3-4, or F4 were 1.66–6.25 and 0.23–0.80, 1.89–5.24 and 0.12–0.64, and 1.32–7.15 and 0.15–0.86, respectively; LR+ and LR− for NAFLD F2-4, F3-4, and F4 were 2.65–3.37 and 0.37–0.39, 2.25–6.76 and 0.07–0.87, and 3.90 and 0.15, respectively. Overall, the proportional odds ratio indicated FIB-4 <1.45 was better than aspartate aminotransferase-to-platelet ratio index 3.25 was also better than aspartate aminotransferase-to-platelet ratio index >1.5 for F3-4 and F4. There was limited data for combined tests. Conclusions: Blood-based biomarkers are associated with small-to-moderate change in pretest probability for diagnosing F2-4, F3-4, and F4 in viral hepatitis, HIV-HCV coinfection, and NAFLD, with limited comparative or combination studies for other chronic liver diseases.

15 March 2024 in Hepatology
Verified
Journal Article
Closed access
RSRichard K. Sterling
Richard K. Sterling
SASumeet K. Asrani
Sumeet K. Asrani
DLDeborah Levine
Deborah Levine
ADAndres Duarte-Rojo
Andres Duarte-Rojo
KPKeyur Patel
Keyur Patel
DRDon C. Rockey
Don C. Rockey
An abstract is unavailable. This article is available as a PDF only.